The week in pharma: action, reaction and insight – week to January 19, 2024

21 January 2024

By Barbara Obstoj-Cardwell. Editor

Last Tuesday, US biotech Aclaris Therapeutics announced that its chief executive would be stepping down and that the company is undertaking a review of its business and development of its dermatology candidates ATI-1777 and ATI-2138. US biotech Allakos suffered a further set back with its lirentelimab in trials for dermatitis and urticaria, leading to a decision to discontinue development. US biotech BridgeBio Pharma has agreed a deal to add up to $1.25 billion to its cash pile in a bid to progress its cardiovascular candidate acoramidis. Dutch biotech argenx gained Japanese approval for its myasthenia gravis drug Vyvdura/Vyvgart.

Leadership change and business review see Aclaris leap

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK